Literature DB >> 16368995

Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits.

Shay Weiss1, David Kobiler, Haim Levy, Hadar Marcus, Avi Pass, Nili Rothschild, Zeev Altboum.   

Abstract

Correlates between immunological parameters and protection against Bacillus anthracis infection in animals vaccinated with protective antigen (PA)-based vaccines could provide surrogate markers to evaluate the putative protective efficiency of immunization in humans. In previous studies we demonstrated that neutralizing antibody levels serve as correlates for protection in guinea pigs (S. Reuveny et al., Infect. Immun. 69:2888-2893, 2001; H. Marcus et al., Infect. Immun. 72:3471-3477, 2004). In this study we evaluated similar correlates for protection by active and passive immunization of New Zealand White rabbits. Full immunization and partial immunization were achieved by single and multiple injections of standard and diluted doses of a PA-based vaccine. Passive immunization was carried out by injection of immune sera from rabbits vaccinated with PA-based vaccine prior to challenge with B. anthracis spores. Immunized rabbits were challenged by intranasal spore instillation with one of two virulent strains (strains Vollum and ATCC 6605). The immune competence was estimated by measuring the level of total anti-PA antibodies, the neutralizing antibody titers, and the conferred protective immunity. The results indicate that total anti-PA antibody titers greater than 1 x 10(5) conferred protection, whereas lower titers (between 10(4) and 10(5)) provided partial protection but failed to predict protection. Neutralizing antibody titers between 500 and 800 provided partial protection, while titers higher than 1,000 conferred protection. In conclusion, this study emphasizes that regardless of the immunization regimen or the time of challenge, neutralizing antibody titers are better predictors of protection than total anti-PA titers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368995      PMCID: PMC1346658          DOI: 10.1128/IAI.74.1.394-398.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans.

Authors:  P R Pittman; J A Mangiafico; C A Rossi; T L Cannon; P H Gibbs; G W Parker; A M Friedlander
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

2.  Identification of strain specific markers in Bacillus anthracis by random amplification of polymorphic DNA.

Authors:  Haim Levy; Morly Fisher; Naomi Ariel; Zeev Altboum; David Kobiler
Journal:  FEMS Microbiol Lett       Date:  2005-03-01       Impact factor: 2.742

3.  Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin.

Authors:  P F Fellows; M K Linscott; B E Ivins; M L Pitt; C A Rossi; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

4.  Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.

Authors:  David Kobiler; Yehoshua Gozes; Hagai Rosenberg; Dino Marcus; Shaul Reuveny; Zeev Altboum
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.

Authors:  Zeev Altboum; Yehoshua Gozes; Ada Barnea; Avi Pass; Moshe White; David Kobiler
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Authors:  M L Pitt; S F Little; B E Ivins; P Fellows; J Barth; J Hewetson; P Gibbs; M Dertzbaugh; A M Friedlander
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

Review 7.  Anthrax vaccines.

Authors:  A M Friedlander; S L Welkos; B E Ivins
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

8.  Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Authors:  S F Little; B E Ivins; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

Review 9.  Anthrax toxin.

Authors:  R John Collier; John A T Young
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

10.  Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine.

Authors:  Hadar Marcus; Rachel Danieli; Eyal Epstein; Baruch Velan; Avigdor Shafferman; Shaul Reuveny
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

View more
  35 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

3.  Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Authors:  Orit Gat; Haim Grosfeld; Naomi Ariel; Itzhak Inbar; Galia Zaide; Yehoshua Broder; Anat Zvi; Theodor Chitlaru; Zeev Altboum; Dana Stein; Sara Cohen; Avigdor Shafferman
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.

Authors:  Itai Glinert; Elad Bar-David; Assa Sittner; Shay Weiss; Josef Schlomovitz; Amir Ben-Shmuel; Adva Mechaly; Zeev Altboum; David Kobiler; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Authors:  Miriam M Ngundi; Bruce D Meade; Stephen F Little; Conrad P Quinn; Cindi R Corbett; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

6.  Antibiotics cure anthrax in animal models.

Authors:  Shay Weiss; David Kobiler; Haim Levy; Avi Pass; Yakir Ophir; Nili Rothschild; Arnon Tal; Josef Schlomovitz; Zeev Altboum
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

8.  A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.

Authors:  Jessica A Chichester; Slobodanka D Manceva; Amy Rhee; Megan V Coffin; Konstantin Musiychuk; Vadim Mett; Moneim Shamloul; Joey Norikane; Stephen J Streatfield; Vidadi Yusibov
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

9.  Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model.

Authors:  Johnny W Peterson; Jason E Comer; Wallace B Baze; David M Noffsinger; Autumn Wenglikowski; Kristin G Walberg; Jason Hardcastle; Jennifer Pawlik; Kathryn Bush; Joanna Taormina; Scott Moen; John Thomas; Bagram M Chatuev; Laurie Sower; Ashok K Chopra; Lawrence R Stanberry; Ritsuko Sawada; Wolfgang W Scholz; Jagadish Sircar
Journal:  Infect Immun       Date:  2007-04-23       Impact factor: 3.441

10.  The physiologic responses of Dutch belted rabbits infected with inhalational anthrax.

Authors:  William S Lawrence; Jason M Hardcastle; Douglas L Brining; Lori E Weaver; Cindy Ponce; Elbert B Whorton; Johnny W Peterson
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.